ARGX - argenx NV ADR - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ARGX is currently covered by 22 analysts with an average price target of $713.75. This is a potential upside of $117.55 (19.72%) from yesterday's end of day stock price of $596.2.

argenx NV ADR's activity chart (see below) currently has 205 price targets and 284 ratings on display. The stock rating distribution of ARGX is 89.58% BUY and 10.42% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 91.44% with an average time for these price targets to be met of 197.46 days.

Highest price target for ARGX is $1100, Lowest price target is $510, average price target is $680.67.

Most recent stock forecast was given by DAVID NIERENGARTEN from WEDBUSH on 11-Apr-2025. First documented stock forecast 16-Nov-2017.

Currently out of the existing stock ratings of ARGX, 129 are a BUY (89.58%), 15 are a HOLD (10.42%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$715

$134.06 (23.08%)

$560

6 days ago
(11-Apr-2025)

15/16 (93.75%)

$134.06 (23.08%)

127

Buy

$720

$139.06 (23.94%)

$720

6 days ago
(11-Apr-2025)

27/30 (90%)

$139.06 (23.94%)

160

Buy

$1100

$519.06 (89.35%)

$665

1 months 7 days ago
(10-Mar-2025)

12/13 (92.31%)

$529 (92.64%)

155

Hold

$680

$99.06 (17.05%)

$650

1 months 13 days ago
(04-Mar-2025)

10/11 (90.91%)

$58.75 (9.46%)

160

Buy

$704

$123.06 (21.18%)

$675

1 months 20 days ago
(28-Feb-2025)

2/4 (50%)

$79.3 (12.69%)

56

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ARGX (argenx NV ADR) average time for price targets to be met?

On average it took 197.46 days on average for the stock forecasts to be realized with a an average price target met ratio 91.44

Which analyst has the current highest performing score on ARGX (argenx NV ADR) with a proven track record?

DANIELLE BRILL

Which analyst has the most public recommendations on ARGX (argenx NV ADR)?

Danielle Brill works at RAYMOND JAMES and has 7 price targets and 7 ratings on ARGX

Which analyst is the currently most bullish on ARGX (argenx NV ADR)?

Yatin Suneja with highest potential upside - $519.06

Which analyst is the currently most reserved on ARGX (argenx NV ADR)?

Tiago Fauth with lowest potential downside - -$261.94

argenx NV ADR in the News

Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) with a favorable safety profile. ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart’s bi-weekly...

argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP

argenx SE ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo’s durable efficacy, sustained functional improvements and favorable safety profile argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?